Table 2.

Summary of the correlations of EZH2 and TTF-1 protein expression and clinicopathological and molecular features of lung adenocarcinomas (N = 320)

EZH2TITF-1
FeaturesCategoriesCases N (%)MeanMedianPMeanMedianP
Age< Mediana16071.1061.50<0.0001132.58160.000.964
≥ Mediana16042.0620.00128.96144.00
SexMale143 (55.3)59.0950.000.336114.29135.000.002
Female177 (44.7)54.5630.00144.09160.00
Smoking statusNever54 (16.9)23.140.00<0.0001147.10160.000.162
Ever266 (83.11)63.3750.00127.46148.50
Tumor size (average)< Meanb162 (62.2)49.0427.500.064146.48160.000.001
≥ Meanb158 (37.8)64.3150.00114.68125.00
TNMI203 (63.5)51.2323.330.024141.42153.000.019
II74 (23.1)66.0058.33108.24112.00
III43 (13.4)65.6460.00119.32143.00
Histology patternNo-solid195 (60.9)39.9316.67<0.0001140.95160.000.015
Any solid (>5%)125 (40.1)82.5673.33114.90123.00
 Solid <40%7070.7860.000.001129.8143.000.013
 Solid ≥40%5597.5586.6795.92100.00
EGFR mutationNegative252 (89.0)60.6046.670.001c121.64140.000.007
Positive33 (11.0)29.903.33167.45180.00
KRAS mutationNegative226 (76.9)57.2040.000.768125.00160.000.375
Positive68 (23.1)51.9643.33134.61140.00
 Cys substitutions3258.3860.000.022162.40180.000.005
 Other substitutions3646.2521.60109.91126.50
  • a66.3 years.

  • b2.7 cm.

  • cNo significant (P = 0.165) after adjusting by smoking.